Can a daily pill stop keloids from coming back?
NCT ID NCT06373458
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug ritlecitinib can prevent keloids from returning after surgical removal. Keloids are raised, often itchy scars that grow beyond the original wound. The trial will enroll 30 adults who will take a daily pill for 36 weeks. Researchers will measure keloid recurrence and severity using a special scale and a skin hardness device.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ritlecitinib (a JAK inhibitor drug taken as a daily pill)
What this could lead to
If successful, this could point toward a new treatment option that reduces keloid recurrence and severity after surgery.
What could go wrong
This is a small, early-phase (2a) trial with only 30 participants, so results may not apply to everyone. The drug may not work better than existing treatments, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KELOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••